Alnylam Pharmaceuticals just delivered the worst single-day drop in recent memory, collapsing 28% on July 30 to $205.48 after its earnings print triggered an immediate and sweeping analyst response.
The catalyst was clearly the earnings release itself. ALNY fell 28% on the day and is now down 30% over the past month — a violent move that has left the stock off roughly 48% year-to-date. The closest correlated peers absorbed far smaller shocks: IONS fell 4.6% on the week, SRPT dropped 2%, and ACAD actually gained 6.9%. The idiosyncratic nature of ALNY's move points squarely at company-specific news rather than sector-wide selling.
The Street's reaction was swift and uniform in direction, but notably not in conviction on ratings. Every firm that updated targets on July 31 cut — Morgan Stanley took its target from $400 to $300, Oppenheimer dropped from $500 to $350, Wells Fargo moved from $377 to $316, Stifel from $444 to $318, and Needham from $510 to $357. Yet every one of them held their existing ratings. Oppenheimer, Stifel, and Needham kept Outperform or Buy. Morgan Stanley and Wells Fargo stayed at Equal-Weight. The message from the Street is consistent: the thesis is damaged, not dead, but valuation needs to reset. The consensus mean price target now sits near $397, implying roughly 93% upside from $205 — a gap that reflects how severely the market has repriced the stock, not renewed optimism. A note of caution: the mean is pulled upward by pre-cut targets still filtering in; the freshest targets cluster in the $300–$360 range, which implies 46%–75% upside at current levels.
The bull case still centres on the TTR franchise's long-term potential — bulls cite a path to $20 billion in revenues and the pipeline depth of Nucresiran and AMVUTTRA. The bear case now carries more weight: slow AMVUTTRA adoption, mostly driven by new prescribers rather than switching, and Phase 3 trial delays into 2027 suggest near-term revenue momentum may disappoint. EV/EBITDA has re-rated sharply, dropping 6.3 points over the past 30 days to 20.2x. The price-to-book multiple has compressed by 4.4 points to 8.6x over the same period. Both moves accelerated on the earnings day itself, with single-day drops of 5.7 and 3.1 points respectively.
Short interest tells a notably calm story against this backdrop. Short interest in ALNY is 4.3% of the free float — a moderate level that has barely moved, up just 3% on the week. Borrow costs remain extremely low at 0.41%, and availability is exceptionally loose at nearly 4,871% of short interest. Over 92 million shares are available to lend against roughly 5.7 million currently borrowed. There is no evidence of a short squeeze setup, but equally no sign that short sellers built aggressive positions ahead of the print or are rushing in afterwards. The ORTEX short score of 38.9 has actually edged down slightly over the past two weeks, reinforcing a picture of modest rather than aggressive bearish positioning.
Options positioning is similarly subdued. The put/call ratio is running at 0.55 — almost exactly in line with its 20-day average of 0.55, with a z-score near zero. That's a striking contrast to the scale of the price move: options traders were not especially defensive heading into the print, and the panic is showing up in the stock rather than in derivatives positioning. One longer-run data point worth noting: the PCR reached its 52-week high of 1.22 at some point this past year, suggesting markets have at times been far more hedged on ALNY than they were heading into this week's result.
Institutional ownership tells a partial story. Capital Research held 15.3% as of June 30, FMR (Fidelity) 10.6%, and T. Rowe Price added more than 3.1 million shares in the quarter to reach 5.0%. Those accumulation flows predate the earnings shock — how these holders respond to a stock that has now lost nearly half its value year-to-date will be the institutional narrative to track through the next 13-F cycle.
ALNY's next earnings event is scheduled for August 6. The key question heading into that date — and the weeks beyond — is whether the AMVUTTRA adoption trajectory showed any improvement in the most recent quarter, and whether management offers any revised guidance on the Phase 3 timeline that could stabilise the Street's rapidly moving price targets.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
